Hikal Limited has informed the Exchange regarding Board meeting held on August 07, 2025 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30 , 2025
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 5.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hikal Limited reported weak Q1 FY26 results with standalone revenue from operations falling to Rs 3,804 million from Rs 4,068 million in the same quarter last year, a decline of about 6.5%. The company swung to a standalone loss before tax of Rs 307 million (vs profit of Rs 70 million in Q1 FY25) and a loss after tax of Rs 227 million (vs profit of Rs 52 million), translating to an EPS of Rs (1.84). Consolidated results also showed a loss after tax of Rs 224 million. The Pharmaceuticals segment saw revenue fall sharply to Rs 2,026 million (from Rs 2,294 million) and posted a segment loss of Rs 261 million, while the Crop Protection segment remained roughly flat at Rs 1,778 million with a profit of Rs 173 million. Auditor SRBC & Co LLP issued an unmodified limited review conclusion but highlighted as an emphasis of matter the ongoing environmental non-compliance case pending before the Supreme Court involving potential compensation of Rs 174.5 million.
Shareholders should brace for a negative market reaction given the sharp swing from profit to loss, double-digit percentage drop in profit metrics, and weakness in the core pharmaceuticals business. The unresolved environmental case continues to be a regulatory overhang, though the Supreme Court has stayed the compensation order for now.